Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial
Go back to Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial| Array Biopharma, Inc. (NASDAQ: ARRY) | Delayed: 4.24 +0.04 (0.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.20 | 52 Week High | $7.27 | |||
| Open | $4.30 | 52 Week Low | $2.39 | |||
| Day High | $4.36 | P/E | N/A | |||
| Day Low | $4.22 | EPS | $-0.61 | |||
| Volume | 4,354,209 | |||||
